CDMOs vs CROs vs CMOs: Understanding Key Services at Each Stage of Drug Development

Every drug that reaches a patient passes through the hands of specialists most people never hear of. CROs, CMOs, and CDMOs quietly run the $270+ billion engine behind modern drug development and picking the wrong one at the wrong stage can cost you months, millions, or your entire timeline.

From early research through to commercial manufacturing, different organizations – Contract Research Organizations (CROs), Contract Manufacturing Organizations (CMOs), and Contract Development and Manufacturing Organizations (CDMOs) – specialize in supporting specific phases of the drug development pipeline.

Understanding when to engage each type of partner can significantly impact your development timeline, costs, and ultimately, your product’s success.

The scale of this outsourcing ecosystem has grown substantially. PharmaSource estimates the global CDMO market at approximately $220 billion in 2025, rising to $236 billion in 2026, with projections reaching $420 billion by 2032–2034.

Key Differences Between CDMOs, CROs, and CMOs

What is a CRO?

Contract Research Organizations (CROs) specialize in the research and clinical development phases of drug development. Their expertise lies in managing clinical trials, conducting research studies, and handling regulatory compliance.

CROs provide services such as protocol development, patient recruitment, clinical monitoring, data management, and regulatory submissions. They are crucial partners for companies focusing on drug discovery and clinical development.

What is a CDMO?

Contract Development and Manufacturing Organizations (CDMOs) offer the most comprehensive service package in the pharmaceutical outsourcing landscape. They provide end-to-end solutions that span from early drug development through to commercial manufacturing.

A CDMO’s services include formulation development, process optimization, analytical method development, scale-up operations, clinical trial material production, and commercial manufacturing. This integrated approach means pharmaceutical companies can work with a single partner throughout their product’s lifecycle, reducing technology transfer risks and potentially accelerating time to market.

It’s worth noting that CDMO capability varies significantly by modality. A CDMO strong in small molecule oral solids won’t necessarily have the specialized infrastructure needed for biologics, antibody-drug conjugates, or cell and gene therapies — each requires distinct facilities, analytical methods, and regulatory track records. Confirming modality-specific experience should be a first-pass filter before deeper due diligence begins.

• • Read Biopharma CDMOs explained

What is a CMO?

Contract Manufacturing Organizations (CMOs) focus specifically on the manufacturing aspect of pharmaceutical products. Unlike CDMOs, they typically enter the picture once a drug formulation has been finalized and requires large-scale production.

CMOs excel in efficient, compliant manufacturing processes, offering services such as commercial-scale production, packaging, and quality control testing. They are ideal partners for companies that have already developed their products and need reliable, high-quality manufacturing capabilities.

The Drug Development Pipeline: Which Partner When?

Each organization type offers distinct services along the drug development pipeline. as explored in our infographic below.

The infographic also includes the services outsourcing partners provide at each stage, industry estimates on the time duration at each stage and the percentage of total budget that is typically allocated to outsourcing at each stage.

The remainder of budget is typically spent on the internal costs such as personnel (including scientific leadership, project management, quality and partner oversight, regulatory affairs and technical operations and infrastructure (including core facilities and office overheads, quality and data management systems).

Mapping services to the drug development timeline

Discovery and Preclinical Stages

During these early stages, outsourcing is at its lowest, with internal costs can represent 80% of budget. Contract Research Organizations (CROs) play a pivotal role at these stages with their specialized research capabilities and laboratory infrastructure support critical activities including:

• • High-throughput screening and lead identification

• • Preclinical safety and efficacy studies

• • GLP toxicology testing

• • Early analytical method development

• • Regulatory documentation for IND/CTA filing

Phase I success rates have fallen sharply industry-wide, from over 75% in 2006–08 to below 40% in recent years — partly due to earlier, biomarker-driven termination of weak programs. Later-stage transition rates hold up better: roughly 64% of programs advance from Phase I to Phase II, 32% from Phase II to Phase III, and 60% from Phase III to NDA submission.

CDMOs may also enter the picture at this stage if early process development and manufacturing considerations are crucial to your strategy. They can provide:

• • Initial process development

• • Analytical method development

• • Preliminary formulation studies

• • Early-stage manufacturing planning

Clinical Development Phases

Phase 1 (Safety Testing)

At this stage, you’ll likely need both CRO and CMO/CDMO support:

CROs manage:

• • Clinical trial design and protocol development

• • Patient recruitment and screening

• • Safety monitoring and reporting

• • Data management and analysis

CMOs/CDMOs handle:

• • Clinical trial material production

• • Initial scale-up activities

• • Quality system implementation

• • Stability testing

Phase 2 (Efficacy Testing)

As trials expand, the role of each partner becomes more crucial:

CROs focus on:

• • Multi-site trial management

• • Expanded patient recruitment

• • Efficacy data collection and analysis

• • Regulatory compliance

CMOs/CDMOs concentrate on:

• • Process optimization

• • Larger-scale manufacturing

• • Quality system harmonization

• • Supply chain planning

 

Phase 3 (Large Trials)

At this pivotal stage, all partners play critical roles:

CROs manage:

• • Large-scale clinical trials

• • Global site coordination

• • Comprehensive data analysis

• • Regulatory submissions

CMOs/CDMOs prepare for commercialization through:

• • Process validation

• • Commercial-scale manufacturing preparation

• • Supply chain optimization

• • Quality system integration

 

Commercial Stage

As products move to market, CMOs and CDMOs take center stage:

• • Commercial-scale manufacturing

• • Ongoing stability studies

• • Post-market change management

• • Supply chain optimization

Geographic and Supply-Chain Risk: A New Factor in Partner Selection

Choosing a CDMO or CMO is no longer purely a technical and cost decision — geopolitics now plays a direct role, particularly for companies with US government funding, Medicare/Medicaid exposure, or long-term dependency on China-based manufacturing.

The BIOSECURE Act was signed into law on December 18, 2025 as part of the FY2026 National Defense Authorization Act, restricting US government procurement from and grants to companies designated “biotechnology companies of concern.” Existing contracts get a five-year safe harbor, but WuXi AppTec — one of the industry’s largest CDMOs — was added to the Department of Defense’s 1260H list in June 2026, a key step toward formal designation under the Act.

This isn’t a niche exposure. A BIO survey found 79% of biopharma and biotech companies currently have a product or contract with a Chinese CMO or CDMO, and a separate industry survey found over a quarter of life science companies were already actively shifting sourcing away from Chinese partners — well ahead of any regulatory deadline.

What to factor into partner selection now:

• Ask prospective CDMO/CMO partners directly about ownership structure and any Chinese state affiliation, even if they’re not currently on a restricted list.
• If you receive federal funding — or sell into Medicare/Medicaid — the Act’s “contractor flow-down” provision means your entire supply chain needs to be compliant, not just your direct contract.
• Build tech transfer lead time into your planning if you’re moving programs off a Chinese CDMO; replacement capacity in sterile fill/finish and specialized modalities is already tight industry-wide.
• Treat this as a live diligence item, not a one-time check — designation lists are updated periodically

What to Evaluate Before You Sign: Selection and Due Diligence

Partner selection mistakes are expensive to reverse mid-program. In one documented case, a sponsor selected a CDMO simply because it could start two weeks sooner than an alternative — skipping due diligence entirely. The CDMO ultimately couldn’t support one of the product’s key target markets, and the decision had to be unwound.

To avoid this, assemble a cross-functional core team — spanning procurement, quality, regulatory, and supply chain — before contacting potential partners, not after a shortlist is chosen.

Key diligence questions to ask during evaluation, drawn from conversations with sourcing leaders:

• Customer retention: What percentage of the CDMO’s top 20 customers from five years ago remain today? High churn signals operational or quality issues.
• Capacity utilization: Are their sites well-invested and running at optimal capacity, or stretched thin?
• Technology differentiation: How broad and unique are their capabilities relative to competitors in your modality?
• On-time delivery performance: Track record matters as much as technical capability on paper.
• Regulatory standing: FDA warning letter history, inspection outcomes, and CAPA closure performance.
• Financial stability and ownership: Especially relevant given current supply-chain and geopolitical scrutiny

Request documentation for all claims, and don’t skip a facility audit or site visit — vague claims without supporting data are a common red flag.